J Korean Surg Soc.  1997 Apr;52(4):566-571.

Actual Half-Life of Alpha-Fetoprotein as a Prognostic Tool in Pediatric Malignant Tumors

Affiliations
  • 1Division of Pediatric Surgery, Department of Surgery, Yonsei University College of Medicine, Korea.
  • 2Department of Surgery, Yonsei University Wonju College of Medicine, Korea.

Abstract

In a retrospective study, the prognostic value of monitoring the decay of alpha-fetoprotein (AFP) was assessed. Serum AFP was determined serially in 18 children with malignant germ cell tumors or malignant hepatic tumors: Fifteen children had malignant germ cell tumors (endodermal sinus tumor;7, embryonal carcinoma;3, malignant teratoma;5). Two children had hepatoblastoma and a third had hepatocellular carcinoma. The actual half-life (AHL) of AFP was computed according to the formula after the surgical resection of the tumor. In group 1, which had a complete resection and no recurrence during follow-up (n=13), the AHL of AFP was 4.0+/-0.9 days. In group 2, which had a incomplete resection or recurrence during follow-up (n=5), the AHL of AFP was 24.8+/-20 days. The AHL of group 2 was significantly longer than that of group 1 (p = 0.0026). The increased AHL of AFP indicated the residual active tumor after surgical resection. The AHL of AFP may be more sensitive than the serial monitoring of AFP in detecting the preclinical recurrence after surgical resection of AFP secreting tumors. Treatment strategies can be based on AFP clearance and prospective clinical trials are warranted.

Keyword

Actual half life; Alpha-fetoprotein; Malisnant germ cell tumor; Hepatic malignancy

MeSH Terms

alpha-Fetoproteins*
Carcinoma, Hepatocellular
Child
Follow-Up Studies
Half-Life*
Hepatoblastoma
Humans
Neoplasms, Germ Cell and Embryonal
Recurrence
Retrospective Studies
alpha-Fetoproteins
Full Text Links
  • JKSS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr